Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587433 | 0.95 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL581832 | 0.90 | NOTUM (0.44) | SMN1; SMN2L3MBTL1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3079872 | 0.87 | OPRK1 (0.41) | SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL587352 | 0.87 | SLC6A3 (0.44) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL582040 | 0.87 | ALDH1A1 (0.48) | SMN1; SMN2SLC6A4SLC6A3SLC6A2MEN1 | |
| SCHEMBL586744 | 0.85 | SLC6A2 (0.46) | SMN1; SMN2SLC6A2MEN1KMT2A | |
| SCHEMBL586946 | 0.84 | TDP1 (0.45) | — | |
| SCHEMBL586843 | 0.84 | SLC6A4 (0.47) | SLC6A4 | |
| SCHEMBL586638 | 0.84 | DPP4 (0.39) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL586604 | 0.83 | OPRK1 (0.43) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | SMN1; SMN2 2619/4885L3MBTL1 2644/4885SLC6A4 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.